Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Healis, CKD Bio Ink Supply Deal to Develop Neuromodulator Protein | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Healis, CKD Bio Ink Supply Deal to Develop Neuromodulator Protein

Aims to develop CKDB-501 for major depressive disorder and post-traumatic stress disorder.

By: Anthony Vecchione

Healis Therapeutics has entered into a supply agreement with CKD Bio Corporation, a subsidiary of Chong Kun Dang group, for CKDB-501, a neuromodulator BoNT/A protein.

Healis Therapeutics intends to develop CKDB-501 for major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). In addition, Healis plans to enter clinical trials in the U.S. and other countries.

According to Healis, ten randomized controlled trials conducted in five countries to date have shown promising early results on glabellar Botulinum Toxin Type A (BoNT/A) treatments for Major Depressive Disorder (MDD).

“We are excited to work with CKD Bio, a global leader in biologics, on a collaboration to develop CKDB-501 for MDD and PTSD,” said Eric Finzi, co-Founder of Healis. “We hope this partnership will accelerate the development of BoNT/A as a potential on-label treatment available to millions of MDD and PTSD patients worldwide.”

Sebastian De Beurs, co-Founder of Healis said, “Our collaboration with CKD Bio on this new agreement could one day impact over 42 million Americans. This planned clinical development represents the largest patient population and market opportunity of any therapeutic indication in the history of BoNT/A.”


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics